Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Sarcoma 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1

Interventions

Fluorouracil 145Gemcitabine 141Oxaliplatin 135Capecitabine 133Leucovorin 107Irinotecan 99Bevacizumab 92Cetuximab 69Cisplatin 67pembrolizumab 61Radiotherapy 60Nivolumab 41130-nm albumin-bound paclitaxel 41Sorafenib 39Docetaxel 34Albumin-Bound Paclitaxel 31Radiosurgery 28Paclitaxel 27Surgical Procedures, Operative 25regorafenib 24Erlotinib Hydrochloride 23Panitumumab 22Cyclophosphamide 21Celecoxib 20Trastuzumab 19Radiation 18Neoadjuvant Therapy 18IFL protocol 18atezolizumab 17Carboplatin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × STA 9090 × Gastrointestinal × Clear all
NCT01227018 2014-07-23

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
15 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡